*Adempas is approved to treat adults with pulmonary arterial hypertension (PAH) (WHO Group 1). The Adempas clinical studies included mostly patients with WHO functional class II-III symptoms. It is not known if Adempas is safe and effective in children.
WHO=World Health Organization
THERE ARE NOW GENERIC VERSIONS OF ADEMPAS
What are generics?
Generic medications share identical active ingredient, dosage, strength, route of administration, and intended use as brand name medications.
How to maintain your current treatment routine
If you're concerned about a generic substitution occurring to your current Adempas treatment, talk to your doctor about "Dispense as Written."
What is "Dispense as Written"?
"Dispense as Written" is an option your doctor can take in all 50 states that helps to ensure the brand of medicine dispensed at the pharmacy is what was prescribed.
Check your pills to ensure you're receiving what was prescribed
Are you familiar with what your current brand of medicine looks like?
Pharmacies may fill your prescription with a generic without you realizing it. Always check your
pills before taking them. If you believe you've been dispensed a new brand of medicine without
you or your doctor being notified, reach out to customer support at the specialty pharmacy.
How far might Adempas take you?
Adempas has been shown to help increase the ability to walk farther (measured by a 6-minute walk distance [6MWD] test), improve some PAH symptoms, and help slow down the worsening of a patient’s physical condition. A 6MWD test determines how far patients can walk in 6 minutes. Doctors may use it periodically to measure progress.
Worsening of physical condition includes death, heart/lung transplant, a surgery to reduce pressure in the lung, hospitalization for worsening of pulmonary hypertension (PH), start of a new PAH-specific treatment, continued decline in the ability to exercise (measured by a 6MWD test) and some PAH symptoms.
CHANGE IN 6MWD AT THE END OF 12 WEEKS
A 12-week study of 443 adults with PAH (WHO Group 1) showed that patients who took Adempas walked farther during the 6MWD test, compared to patients who did not take Adempas.
50% more patients who took Adempas improved their WHO functional class compared to patients who took a placebo (no Adempas).
21% of Adempas patients showed WHO functional class improvement vs 14% of placebo patients.
Considering Adempas?
Learn more about support for our patients here.